Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
06/12/17
Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection
- Based on recent FDA interactions, the new SER-109 Clinical Study is to be designated a Phase 3 Trial - - SER-109 Phase 3 Trial is the first pivotal trial in the emerging field of microbiome-based oral therapeutics - - Phase 3 Trial initiation triggers a $20 million milestone payment from Nestlé Health Science - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 12, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced the... 
06/06/17
Seres Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 6, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will participate in a webcast discussion at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 13 at 4 p.m. PT. Live audio webcast will be available under the Investors and Media section of Seres’ website. A replay of the presentation will become available approximately... 
06/05/17
Seres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis
- Study results expected in the second half of 2017 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 5, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it has completed enrollment for its ongoing SER-287 Phase 1b clinical study of 58 patients suffering from mild-to-moderate ulcerative colitis who are failing current therapies. SER-287 is the first microbiome therapeutic candidate to reach clinical‐stage development in a chronic inf... 
EventsMore
There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$12.10
 + 0.42 (3.60%)
06/26/17 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.